Navigation Links
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
Date:1/6/2009

LYNBROOK, N.Y., Jan. 6 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, today announced that it has received notification from The NASDAQ Stock Market LLC that its common stock has been approved for listing on the NASDAQ Global Market. The Company's common stock will begin trading January 9, 2009 on NASDAQ at market open under the symbol "BSTC" and will end trading on the OTC Bulletin Board at the close of market on January 8, 2009.

"This listing on NASDAQ marks the culmination of a transformational year for us at BioSpecifics, and we believe it will greatly benefit our stockholders by enhancing our liquidity and overall visibility," stated Thomas L. Wegman, President of BioSpecifics. "In 2008, we announced positive Phase 3 clinical results for our collagenase product XIAFLEX(TM) for Dupuytren's disease and our partner Auxilium initiated the Phase 2b trial for Peyronie's disease. In addition, Auxilium just announced a major European licensing agreement with Pfizer, in which BioSpecifics will receive a share of both the upfront payment and sales and regulatory milestones. We are very much looking forward to further progress, including the filing with the U.S. Food and Administration of the Biologic License Application of XIAFLEX early this year."

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and partnered, injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease, and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in June 2008. Based on those positive Phase III results, Auxilium expects to file a Biologic License Application in early 2009.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
2. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
3. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
4. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
5. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
6. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions to ... symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory science, ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
Breaking Biology Technology:
(Date:8/23/2017)... -- The general public,s help is being enlisted in what,s thought to be ... on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study ... gut. The project's goal is to help advance scientific knowledge of the ... ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
Breaking Biology News(10 mins):